Cargando…
A novel workflow for cancer blood biomarker identification
BACKGROUND: Over the last few years, great progress has been made in the development of key technologies to detect peripheral blood-based, tumor-specific biomarkers, such as circulating tumor cells (CTCs) and circulating cell free tumor DNA (ctDNA). Despite the considerable advances and their multip...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723582/ https://www.ncbi.nlm.nih.gov/pubmed/33313175 http://dx.doi.org/10.21037/atm-20-2047 |
_version_ | 1783620370236964864 |
---|---|
author | Wang, Xiang Qiu, Zhiqiang Ji, Xiangwen Ning, Weihai An, Yihua Wang, Shengdian Zhang, Hongwei |
author_facet | Wang, Xiang Qiu, Zhiqiang Ji, Xiangwen Ning, Weihai An, Yihua Wang, Shengdian Zhang, Hongwei |
author_sort | Wang, Xiang |
collection | PubMed |
description | BACKGROUND: Over the last few years, great progress has been made in the development of key technologies to detect peripheral blood-based, tumor-specific biomarkers, such as circulating tumor cells (CTCs) and circulating cell free tumor DNA (ctDNA). Despite the considerable advances and their multiple clinical values, liquid biopsies are challenged by the very low concentrations of CTCs and ctDNA in blood samples. Additionally, blood biomarkers which were found using data-driven methods may only be effective in few datasets. METHODS: We firstly collected the genes which have expression correlations between blood and the other tissues/organs using Genotype-Tissue Expression (GTEx). Survival hazard genes and differential expression genes of each cancer type in The Cancer Genome Atlas (TCGA) were then selected by Cox regression model and Wilcoxon rank sum test, respectively. By combining the P values of two steps, several blood biomarkers can be inferred for each cancer type. After applying these potential blood biomarker sets to 13 datasets of blood samples from solid tumor patients using single sample gene set enrichment analyses (ssGSEA), we got an enrichment score (ES) for each sample. RESULTS: The inferred blood biomarker (BB infer) genes showed reliable predictive value in various malignancies. In all the blood samples that were analyzed, the ESs of positive BB Infer genes in cancer patients are higher than healthy people. Conversely, the ESs of negative BB Infer genes in cancer patients are lower than healthy people. Furthermore, lower ES of negative BB infer genes signify the dismal outcome of patients. CONCLUSIONS: We developed a novel solid tumor blood biomarker inference workflow for cancer screening and diagnosis. Moreover, we demonstrated the utility of this inference method in a series of blood sample datasets of solid tumor patients. These results suggested the potential value of this method in the screening, diagnosis and prognosis of cancers. |
format | Online Article Text |
id | pubmed-7723582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-77235822020-12-10 A novel workflow for cancer blood biomarker identification Wang, Xiang Qiu, Zhiqiang Ji, Xiangwen Ning, Weihai An, Yihua Wang, Shengdian Zhang, Hongwei Ann Transl Med Original Article BACKGROUND: Over the last few years, great progress has been made in the development of key technologies to detect peripheral blood-based, tumor-specific biomarkers, such as circulating tumor cells (CTCs) and circulating cell free tumor DNA (ctDNA). Despite the considerable advances and their multiple clinical values, liquid biopsies are challenged by the very low concentrations of CTCs and ctDNA in blood samples. Additionally, blood biomarkers which were found using data-driven methods may only be effective in few datasets. METHODS: We firstly collected the genes which have expression correlations between blood and the other tissues/organs using Genotype-Tissue Expression (GTEx). Survival hazard genes and differential expression genes of each cancer type in The Cancer Genome Atlas (TCGA) were then selected by Cox regression model and Wilcoxon rank sum test, respectively. By combining the P values of two steps, several blood biomarkers can be inferred for each cancer type. After applying these potential blood biomarker sets to 13 datasets of blood samples from solid tumor patients using single sample gene set enrichment analyses (ssGSEA), we got an enrichment score (ES) for each sample. RESULTS: The inferred blood biomarker (BB infer) genes showed reliable predictive value in various malignancies. In all the blood samples that were analyzed, the ESs of positive BB Infer genes in cancer patients are higher than healthy people. Conversely, the ESs of negative BB Infer genes in cancer patients are lower than healthy people. Furthermore, lower ES of negative BB infer genes signify the dismal outcome of patients. CONCLUSIONS: We developed a novel solid tumor blood biomarker inference workflow for cancer screening and diagnosis. Moreover, we demonstrated the utility of this inference method in a series of blood sample datasets of solid tumor patients. These results suggested the potential value of this method in the screening, diagnosis and prognosis of cancers. AME Publishing Company 2020-11 /pmc/articles/PMC7723582/ /pubmed/33313175 http://dx.doi.org/10.21037/atm-20-2047 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Wang, Xiang Qiu, Zhiqiang Ji, Xiangwen Ning, Weihai An, Yihua Wang, Shengdian Zhang, Hongwei A novel workflow for cancer blood biomarker identification |
title | A novel workflow for cancer blood biomarker identification |
title_full | A novel workflow for cancer blood biomarker identification |
title_fullStr | A novel workflow for cancer blood biomarker identification |
title_full_unstemmed | A novel workflow for cancer blood biomarker identification |
title_short | A novel workflow for cancer blood biomarker identification |
title_sort | novel workflow for cancer blood biomarker identification |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723582/ https://www.ncbi.nlm.nih.gov/pubmed/33313175 http://dx.doi.org/10.21037/atm-20-2047 |
work_keys_str_mv | AT wangxiang anovelworkflowforcancerbloodbiomarkeridentification AT qiuzhiqiang anovelworkflowforcancerbloodbiomarkeridentification AT jixiangwen anovelworkflowforcancerbloodbiomarkeridentification AT ningweihai anovelworkflowforcancerbloodbiomarkeridentification AT anyihua anovelworkflowforcancerbloodbiomarkeridentification AT wangshengdian anovelworkflowforcancerbloodbiomarkeridentification AT zhanghongwei anovelworkflowforcancerbloodbiomarkeridentification AT wangxiang novelworkflowforcancerbloodbiomarkeridentification AT qiuzhiqiang novelworkflowforcancerbloodbiomarkeridentification AT jixiangwen novelworkflowforcancerbloodbiomarkeridentification AT ningweihai novelworkflowforcancerbloodbiomarkeridentification AT anyihua novelworkflowforcancerbloodbiomarkeridentification AT wangshengdian novelworkflowforcancerbloodbiomarkeridentification AT zhanghongwei novelworkflowforcancerbloodbiomarkeridentification |